企業概要
Zoetis Inc. is a global leader in the animal health sector, specializing in the discovery, development, manufacturing, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision animal health solutions for the United States and international markets. The company operates within the Healthcare sector, specifically classified under the Drug Manufacturers - Specialty & Generic industry, which positions it as a critical provider of essential pharmaceutical and biological products for livestock and companion animals. Zoetis Inc. demonstrates substantial scale with a market capitalization of $52.77B, an annual revenue of $9.47B, and a workforce comprising 14,500 employees. These valuation and revenue figures indicate that the company holds a dominant position in its niche, commanding significant market share and maintaining a robust financial footprint that supports extensive research and development initiatives across its global operations.
財務健全性
Zoetis Inc. reported a trailing twelve-month revenue of $9.47B, generating net income of $2.67B and an EBITDA of $4.07B. The gap between the $9.47B revenue and the $2.67B net income reveals a highly efficient cost structure, where the company retains a significant portion of its top-line growth after accounting for operating expenses, taxes, and interest. The business generated free cash flow of $1.79B, which signifies strong financial flexibility allowing the firm to fund capital expenditures, service its debt obligations, and potentially return capital to shareholders without compromising operational liquidity. Profitability is underpinned by exceptional margins, including a gross margin of 71.9%, an operating margin of 34.7%, and a profit margin of 28.2%, each indicating the company's ability to maintain high pricing power and control over its supply chain and manufacturing costs. Regarding leverage, the company holds $2.31B in cash against $9.31B in debt, resulting in a debt-to-equity ratio of 279.59, which suggests a capital structure heavily reliant on equity financing rather than debt service. Despite the high debt figure, the current ratio of 3.03 indicates a highly conservative balance sheet with ample short-term assets available to cover liabilities, ensuring robust liquidity management. Furthermore, the return on equity of 66.0% and return on assets of 15.3% reveal that management is effectively utilizing shareholder capital and total assets to generate superior returns compared to industry averages.
バリュエーション評価
The stock trades at a trailing P/E ratio of 19.89 with a forward P/E of 15.87, implying that the market expects a significant acceleration in earnings growth that will cause the valuation multiple to compress over the coming year. The price-to-book ratio stands at 15.28, indicating that the market assigns a substantial premium to Zoetis Inc.'s intangible assets, brand value, and proprietary intellectual property over its tangible book value. Alternative valuation metrics, such as a price-to-sales ratio of 5.57 and an EV/EBITDA of 14.15, suggest that investors are willing to pay a high multiple relative to the company's sales and operating earnings, reflecting confidence in its long-term growth prospects. In terms of price volatility, the stock's 52-week high of $172.23 and 52-week low of $113.29 define a trading range of approximately $58.94, with the current market price situated within this established band relative to historical extremes. The beta value of 0.97 indicates that the stock's price volatility is nearly identical to the broader market, suggesting it behaves as a standard proxy for the overall market rather than acting as a defensive or aggressive hedge.
Growth & Income
Zoetis Inc. is experiencing moderate expansion with a revenue growth rate of 3.0% and an earnings growth rate of 6.1%, indicating that profitability is expanding at a pace faster than top-line sales, which often points to operational efficiencies or favorable mix shifts. As a consistent dividend payer, the company offers a dividend yield of 1.8% backed by a payout ratio of 33.2%, a level that is highly sustainable given the company's robust earnings generation and strong free cash flow conversion. The relatively low payout ratio leaves ample room for the company to reinvest earnings into research and development or acquisitions rather than maximizing dividend payments, balancing income generation with future growth potential. Overall, the company presents a growth and income profile characterized by steady top-line expansion, accelerating earnings growth, and a disciplined approach to capital allocation that supports both current income and long-term value creation.